- Telik's MDS candidate Telintra wins orphan-drug designation
The FDA granted orphan-drug status to Telik's Telintra, or ezatiostat HCL, an experimental drug for myelodysplastic syndrome. In studies, Telintra was associated with multilineage response and the need for fewer red blood cell transfusions among MDS patients. RTT News (1/11)        | Avoiding the Shoebox: Managing Expenses in Small and Mid-Sized Businesses
Small businesses need to efficiently control costs and optimize cash flow, but how, and what role does automation play in this process? This whitepaper helps answers some of those questions. Download the free whitepaper. |
 - Biotest and ADMA Biologics agree to deal for immune globulin
Biotest Pharmaceuticals has entered a 10-year deal to act as the exclusive global supplier to ADMA Biologics for respiratory syncytial virus immune globulin made from human plasma. As part of the agreement, ADMA secured the right to use Biotest's proprietary fractionation and purification technology for the production of intravenous immune globulin. HealthcareGlobal.com (1/11) - Sorrento secures recombinant IVIG manufacturing rights
Sorrento Therapeutics obtained global rights to manufacture recombinant intravenous immunoglobulin using its G-MAB antibody library technology. IVIG is used for treating illnesses such as primary and secondary immunological deficiencies, acute infections and autoimmune diseases. "With the acquisition of the proprietary rights to the rIVIG technology, we now have access to a multi-billion dollar market opportunity applying our G-MAB antibody libraries to address unmet medical needs," STI President and CEO Henry Ji said. Pharmaceutical Business Review Online (1/11) - GeoVax proceeds with trial of investigational HIV vaccine
GeoVax Labs has completed enrollment for a Phase I/II study assessing the safety and immunogenicity of its experimental therapeutic DNA/MVA vaccine in HIV-positive patients whose infections can be controlled with oral drugs. The company could proceed to an early-stage trial of the vaccine with conventional care in young adults, Chief Scientific Officer Harriet Robinson said. Pharmaceutical Business Review Online (1/11) - ArQule, Daiichi report results of tivantinib trial
ArQule and Daiichi Sankyo's tivantinib, in combination with older cancer drugs irinotecan and cetuximab, did not demonstrate a statistically significant difference versus placebo in improving progression-free survival among patients with refractory or relapsed colorectal cancer during a mistage trial. The partners will talk with medical experts in colorectal cancer about how to proceed, and the drug also is in development for liver cancer. Reuters (1/11)  | Dell has your IT wish list covered.
Desktops, laptops and accessories. Save up to 35% on the latest technology for your medical practice. Enable workforce productivity with the budget-friendly Latitude E5430. It offers easy management and integration into an E-Family docking environment. Shop Now. |
 | Company & Financial News |  |  | | | Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - USDA awards $25M in grants to 4 bioenergy research projects
The Department of Agriculture awarded grants amounting to $25 million to four projects that aim to develop fuel and other products from biomass. Agriculture Secretary Tom Vilsack made the announcement at the commissioning of a Renmatix multi-feestock processing plant in King of Prussia, Pa. DomesticFuel.com (1/13) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | You will do foolish things, but do them with enthusiasm."
--Sidonie-Gabrielle Colette,
French novelist and performer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, January 11, 2013
- Thursday, January 10, 2013
- Wednesday, January 09, 2013
- Tuesday, January 08, 2013
- Monday, January 07, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment